|Bid||0.00 x 1200|
|Ask||0.00 x 2900|
|Day's Range||14.50 - 15.37|
|52 Week Range||3.61 - 27.06|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 14, 2018 - May 18, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||37.14|
Two days after Cantor Fitzgerald gave Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) a shot in the arm with an ultrabullish rating , Stifel Nicolaus administered a booster. Galmed spiked 15 percent Friday ...
NEW YORK, NY / ACCESSWIRE / July 13, 2018 / An analyst at Cantor Fitzgerald thinking that Galmed Pharmaceuticals is undervalued in the NASH space had traders cheering on Thursday, sending shares higher ...
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) earned another bullish analyst this week with a positive rating from Cantor Fitzgerald. The coverage comes with a valuation that implies 459-percent upside. The ...
The Nasdaq Composite Index shed 0.55 percent to close at 7,716.61. It’s unclear what it might do next, but it is clearly another step closer to a full-blown trade war,” according to David Carter, chief investment officer at Lenox Wealth Advisors. “If the trade skirmish escalates into a full-blown trade war, that will be a bigger force in the markets than the strong fundamentals,” Carter added.
Dry Eye Syndrome is a huge market in the U.S., where Allergan's (AGN) Restasis has over $1.4 billion in sales annually. Investors haven't noticed, but a newly public Wize Pharma (WIZP) has an alternative drug that has been approved and used in parts of Europe for years. WIZP has U.S. rights to the drug and is running two clinical trials with results from the first to be released in the coming months.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 19) AngioDynamics, Inc. (NASDAQ: ANGO ) Array Biopharma Inc (NASDAQ: ...
TEL AVIV, Israel, June 19, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, today announced that it has priced its previously announced underwritten public offering of 5,000,000 ordinary shares, at a public offering price of $15.00 per share. The gross proceeds to Galmed, before deducting the underwriting discounts and commissions and estimated offering expenses will be $75 million. In addition, Galmed granted the underwriters a 30-day option to purchase up to an additional 750,000 ordinary shares at the public offering price, less the underwriting discounts and commissions.
TEL AVIV, Israel, June 18, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, today announced that it intends to offer and sell, subject to market and other conditions, ordinary shares in an underwritten public offering to raise aggregate proceeds of approximately $75,000,000. In addition, Galmed intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares sold in the offering, at the public offering price, less the underwriting discounts and commissions. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.
The first treatments for this growing epidemic of liver disease will be huge blockbusters, and one of these biotechs could have what it takes.
NEW YORK, NY / ACCESSWIRE / June 15, 2018 / Elon Musk is investing millions in technology to enhance and connect the brain to robots and prosthetics. Upstart NeuroOne Medical (NMTC) could change that with their first FDA approved device, anticipated by the end of this year - a thin-film electrode that was pioneered at The Mayo Clinic. This prestigious institute owns 10% of NMTC, validating the tech.
On June 13, Viking Therapeutics (VKTX) stock rose ~9.1%, triggered by positive mid-stage trial results for peer Galmed Pharmaceuticals’ (GLMD) NASH (non-alcoholic steatohepatitis) drug, Aramchol. For more on the development, read Why Galmed Pharmaceuticals Stock Rose 151% on June 12. Galmed’s positive study results buoyed investors’ hopes of success for Viking Therapeutics’ NASH candidate, VK2809, which is in mid-stage trials and has a similar mechanism of action. On June 13, the SPDR S&P Biotech ETF (XBI) rose ~0.26%.
Shares of Galmed Pharmaceuticals (GLMD) surges significantly following positive top-line results on lead candidate Aramchol in NASH patients.
NEW YORK, NY / ACCESSWIRE / June 13, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Galmed Pharmaceuticals Ltd. (GLMD), a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. On June 12, 2018, the company announced that a phase 2b trial of its ARREST study for the treatment of non-alcoholic steato-hepatitis achieved the endpoints necessary to support a phase 3 trial and a Food and Drug Administration marketing application. NASH is an emerging world crisis impacting an estimated 3% to 5% of the U.S. population and an estimated 2% to 4% globally.
Galmed Pharmaceuticals (GLMD) stock rose 151.3% on June 12. Galmed stock rose after the company announced top-line results from the global 52-week phase 2b ARREST trial. The company is conducting the phase 2b ARREST trial to evaluate the safety and efficacy of its Aramchol for the treatment of individuals with non-alcoholic steatohepatitis (or NASH).
NEW YORK, NY / ACCESSWIRE / June 13, 2018 / It was an exciting day for biotech stocks Sage Therapeutics and Galmed Pharmaceuticals. Sage rose higher after announcing that the FDA has allowed expedited development on its major depressive drug. Shares of Galmed soared to a new high after announcing positive results from its Phase 2b ARREST study.
This study was seeking to determine the effectiveness of using Aramchol to treat non-alcoholic steatohepatitis. Galmed Pharmaceuticals Ltd’s Phase 2b ARREST study saw the company splitting up 247 patients with biopsy-proven NASH that were overweigh or obese into three groups. The second took 400mg of the drug and the third was the placebo group.
Galmed shot up 204% to $21.33 in morning trading, following positive data about its treatment for liver disease nonalcoholic steatohepatitis (NASH). Jefferies' Michael Yee writes that while Galmed's study formally missed statistical significance on both of its regulatory endpoints, "the trial did show significant trends that could hit significance in a larger trial." Given Galmed's size, he notes that Intercept Pharmaceuticals (ICPT) and Gilead Sciences (GILD), both of which have NASH data due out within the next year, could be another way to play the trend, as he anticipates both moving higher on the data. The rest of the sector wasn't doing as well, but was generally higher: The iShares Nasdaq Biotechnology ETF (IBB) is up 0.4% to $110.37, and the SPDR S&P Biotech ETF (XBI) is 0.8% higher to $96.70.